BidaskClub Upgrades Aurinia Pharmaceuticals (AUPH) to “Hold”

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday.

Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity set a $11.00 price objective on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 24th. Zacks Investment Research cut Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 15th. ValuEngine raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $10.79.

Shares of Aurinia Pharmaceuticals (AUPH) traded down $0.07 during midday trading on Thursday, reaching $5.62. The company’s stock had a trading volume of 749,749 shares, compared to its average volume of 1,049,549. Aurinia Pharmaceuticals has a one year low of $2.95 and a one year high of $10.54. The stock has a market capitalization of $477.81, a PE ratio of -4.26 and a beta of 2.35.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Aurinia Pharmaceuticals will post -1.08 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its holdings in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,341 shares during the period. Wells Fargo & Company MN grew its holdings in Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 26,395 shares during the period. Cutler Capital Management LLC grew its holdings in Aurinia Pharmaceuticals by 33.3% during the third quarter. Cutler Capital Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 10,000 shares during the period. Investment Centers of America Inc. grew its holdings in Aurinia Pharmaceuticals by 100.0% during the third quarter. Investment Centers of America Inc. now owns 60,000 shares of the biotechnology company’s stock worth $376,000 after acquiring an additional 30,000 shares during the period. Finally, Kazazian Asset Management LLC grew its holdings in Aurinia Pharmaceuticals by 47.3% during the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 21,304 shares during the period. 28.09% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “BidaskClub Upgrades Aurinia Pharmaceuticals (AUPH) to “Hold”” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/28/bidaskclub-upgrades-aurinia-pharmaceuticals-auph-to-hold.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply